• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Intracamerally injected mydriatic agents in cataract surgery: Good safety profile


Intracamerally injected mydriatic agents safer than standard eye drop regimen during cataract surgery performed in older patients.

The side effects of drugs are always concerns, no matter what the age or general health of patients. However, those concerns are amplified in older populations, particularly those who are at increased risk of cardiovascular events.

“Cataract is associated with old age and, as the population age, the demand for cataract surgery is increasing and will likely continue to increase. Additionally, elderlies are at an increased risk of developing multiple pathologies and are consequently polymedicated,” according to the investigators of a study in which the systemic exposure to the combination of tropicamide/phenylephrine after intracameral or topical administration before performing cataract surgery was evaluated.

This drug combination is considered the gold standard to establish stable mydriasis during cataract surgery with lens implantation. However, Jose Guell, MD, and colleagues pointed out that these drugs usually must be instilled multiple times intraoperatively, which may result in an overdose associated with increased risk of cardiovascular events and ocular surface toxicity, the latter of which can lead to keratopathy and decreased intraoperative visualization.

To avoid prolongation of the time to mydriasis preoperatively with administration of drugs in the surgical center or even at home where the patients are unsupervised, an intracameral fixed combination of mydriatic drugs and an anesthetic (ICMA) at the start of cataract surgery has been investigated and is considered safe and effective.

Dr. Guell et al. noted, “A particular benefit of intracameral mydriatics/anesthetic is the excellent bioavailability directly in the target tissues and the putative lower systemic absorption compared to [eye drop] formulations. The synergistic effect of the two mydriatic components also permits lower doses of each to be used, further limiting the local toxicity of these drugs.” Patients also have been reported to be more comfortable intraoperatively, with less preparatory and surgical time compared with use of drops.
The study

Considering these benefits, the current investigators wanted to determine the systemic exposure experienced by 271 patients receiving the ICMA formulation (tropicamide 0.02%, phenylephrine 0.31%, and lidocaine 1%) in the operated eye compared with 283 patients treated with the standard topical administration (tropicamide 0.5% and phenylephrine 10%), referred to as the safety set. High-performance liquid chromatography was performed before and after administration of the drug regimens to determine the plasma levels in 15 patients in each group.

The investigators reported that 198 patients in the ICMA group received one 200-microliter dose, which exposed them to a calculated level of 0.04 mg of tropicamide and 0.62 mg of phenylephrine; none received an additional mydriatic. In the rest of the ICMA group, 72 patients received another 100-microliter injection for a maximal dose of 0.06 mg of tropicamide and 0.93 mg of phenylephrine; one patient received a third 100-microliter injection.

In the safety set group, the respective exposures with three drops were calculated to be 0.45 and 10.2 milligrams, 11.3-fold and 16.5-fold higher compared with the ICMA group. When patients required additional drops, which occurred in 9.2% of patients, the exposure was 37.5-fold higher for tropicamide (10 drops, 1.5 mg) and 54.8-fold higher for phenylephrine (10 drops, 34 mg) compared with the recommended ICMA dose, the investigators reported.

Results of blood sampling

The mean patient age of the 30 patients who underwent blood sampling was 71.3 years (range, 51.3-85.5); most (80.0%) were older than 65 years. All of these patients received the standard regimen of mydriatics in both groups (except for one patient in the ICMA group who received another 100-microliter injection).

In the 15 patients in the ICMA group, tropicamide was not detected at 2, 12, and 30 minutes after injection but was detected in 73.3% of patients in the safety set group at 2 minutes and in all patients at 12 and 30 minutes (maximal plasma concentration, 3.16 nanograms/milliliter at 30 minutes in the safety set group).

Phenylephrine was detected in the ICMA group in two patients (maximal concentrations, 0.140 and 0.587 nanogram/milliliter) and in all 15 patients in the safety set at least one time point (range of maximal concentration between 0.109 and 1.42 nanogram/milliliter); in 38.5% of patients, the maximal phenylephrine concentration was over 0.59 nanogram/milliliter.

When the two groups were compared, the authors reported that more patients in the safety set group had a “meaningful increase” in hypertension and/or tachycardiac events, that is, 11.2% vs. 6.0% in the ICMA group, respectively, a difference that reached significance (p = 0.03).

The study results showed that the “ICMA result has lower systemic ocular surface exposure to phenylephrine and tropicamide than the … topical treatment. [The ICMA treatment] permits the correct dose of the appropriate agents to be administered consistently at a convenient time (at the start of surgery), in a safe and monitored environment (the operating room) at an appropriate site (anterior chamber) with less [cardiovascular] side effects compared to the usual dilation procedure,” the investigators concluded.

The authors reported their findings on behalf of the Intracameral Mydrane and Ethics Group in Clinical Ophthalmology (2019;13:811-819).


Jose Guell, MD
E: guell@imo.es
Dr. Guell is affiliated with the Autonomous University of Barcelona, Barcelona, Spain.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.